Literature DB >> 18462208

Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.

S von Vietinghoff1, C Eulenberg, M Wellner, F C Luft, R Kettritz.   

Abstract

The neutrophil serine protease proteinase 3 (PR3) is a main autoantigen in anti-neutrophil cytoplasmic antibody-associated vasculitis. PR3 surface presentation on neutrophilic granulocytes, the main effector cells, is pathogenically important. PR3 is presented by the NB1 (CD177) glycoprotein, but how the presentation develops during neutrophil differentiation is not known. An N-terminally unprocessed PR3 (proPR3) is produced early during neutrophil development and promotes myeloid cell differentiation. We therefore investigated if PR3 presentation depended on NB1 during neutrophil differentiation and if PR3 and proPR3 could both be presented by NB1. In contrast to mature neutrophils, differentiating neutrophils showed an early NB1-independent PR3 surface display that was recognized by only two of four monoclonal anti-PR3 antibodies and occurred in parallel with proPR3, but not PR3 secretion, suggesting that the NB1-independent surface PR3 was proPR3. PR3 gene expression preceeded NB1. When the NB1 receptor was detected on the surface, a mode of PR3 surface display similar to mature neutrophils developed together with the degranulation system. Ectopic expression studies showed that NB1 was a sufficient receptor for PR3 but not proPR3. ProPR3 display on the plasma membrane may influence the bone marrow microenvironment. NB1-mediated PR3 presentation depended on PR3 N-terminal processing implicating the PR3-N-terminus as NB1-binding site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462208      PMCID: PMC2453217          DOI: 10.1111/j.1365-2249.2008.03663.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Subcellular fractionation of human neutrophils on Percoll density gradients.

Authors:  L Kjeldsen; H Sengelov; N Borregaard
Journal:  J Immunol Methods       Date:  1999-12-17       Impact factor: 2.303

2.  Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  K A Russell; D N Fass; U Specks
Journal:  Arthritis Rheum       Date:  2001-02

Review 3.  Neutrophil production and function in newborn infants.

Authors:  R Carr
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

4.  Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition.

Authors:  E J Campbell; M A Campbell; C A Owen
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

5.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 6.  Transcriptional regulation of granulocyte and monocyte development.

Authors:  Alan D Friedman
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

7.  Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies.

Authors:  Y M van der Geld; W Oost-Kort; P C Limburg; U Specks; C G Kallenberg
Journal:  J Immunol Methods       Date:  2000-10-20       Impact factor: 2.303

8.  A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein.

Authors:  Lila Farrag; William F Pendergraft; J J Yang; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Autoimmunity       Date:  2007-11       Impact factor: 2.815

9.  Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.

Authors:  Javier D Finkielman; Peter A Merkel; Darrell Schroeder; Gary S Hoffman; Robert Spiera; E William St Clair; John C Davis; W Joseph McCune; Andrea K Lears; Steven R Ytterberg; Amber M Hummel; Margaret A Viss; Tobias Peikert; John H Stone; Ulrich Specks
Journal:  Ann Intern Med       Date:  2007-11-06       Impact factor: 25.391

Review 10.  What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA.

Authors:  U Specks
Journal:  Arthritis Res       Date:  2000-06-12
View more
  16 in total

1.  The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.

Authors:  M Choi; C Eulenberg; S Rolle; J P von Kries; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

Review 4.  How anti-neutrophil cytoplasmic autoantibodies activate neutrophils.

Authors:  R Kettritz
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

5.  Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Hui Liu; Yi Liu; Yi Li; Zhaoyun Liu; Liyan Li; Shaoxue Ding; Yihao Wang; Tian Zhang; Lijuan Li; Zonghong Shao; Rong Fu
Journal:  Exp Ther Med       Date:  2017-12-21       Impact factor: 2.447

6.  Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation.

Authors:  Uwe Jerke; Susanne Rolle; Gunnar Dittmar; Behnaz Bayat; Sentot Santoso; Anje Sporbert; Friedrich Luft; Ralph Kettritz
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

Review 7.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

8.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

9.  Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis.

Authors:  Britta E Jones; Jiajin Yang; Akhil Muthigi; Susan L Hogan; Yichun Hu; Joshua Starmer; Candace D Henderson; Caroline J Poulton; Elizabeth J Brant; William F Pendergraft; J Charles Jennette; Ronald J Falk; Dominic J Ciavatta
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

Review 10.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.